Nature Communications (Mar 2021)
A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes
- Camila H. Coelho,
- Wai Kwan Tang,
- Martin Burkhardt,
- Jacob D. Galson,
- Olga Muratova,
- Nichole D. Salinas,
- Thiago Luiz Alves e Silva,
- Karine Reiter,
- Nicholas J. MacDonald,
- Vu Nguyen,
- Raul Herrera,
- Richard Shimp,
- David L. Narum,
- Miranda Byrne-Steele,
- Wenjing Pan,
- Xiaohong Hou,
- Brittany Brown,
- Mary Eisenhower,
- Jian Han,
- Bethany J. Jenkins,
- Justin Y. A. Doritchamou,
- Margery G. Smelkinson,
- Joel Vega-Rodríguez,
- Johannes Trück,
- Justin J. Taylor,
- Issaka Sagara,
- Jonathan P. Renn,
- Niraj H. Tolia,
- Patrick E. Duffy
Affiliations
- Camila H. Coelho
- Pathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Wai Kwan Tang
- Host-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Martin Burkhardt
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Jacob D. Galson
- Division of Immunology and Children’s Research Center, University Children’s Hospital Zurich, University of Zurich (UZH)
- Olga Muratova
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Nichole D. Salinas
- Host-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Thiago Luiz Alves e Silva
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Karine Reiter
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Nicholas J. MacDonald
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Vu Nguyen
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Raul Herrera
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Richard Shimp
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- David L. Narum
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Miranda Byrne-Steele
- iRepertoire Inc.
- Wenjing Pan
- iRepertoire Inc.
- Xiaohong Hou
- iRepertoire Inc.
- Brittany Brown
- iRepertoire Inc.
- Mary Eisenhower
- iRepertoire Inc.
- Jian Han
- iRepertoire Inc.
- Bethany J. Jenkins
- Pathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Justin Y. A. Doritchamou
- Pathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Margery G. Smelkinson
- Biological Imaging Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Joel Vega-Rodríguez
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Johannes Trück
- Division of Immunology and Children’s Research Center, University Children’s Hospital Zurich, University of Zurich (UZH)
- Justin J. Taylor
- Fred Hutchinson Cancer Research Center
- Issaka Sagara
- Malaria Research and Training Center, University of Sciences, Techniques, and Technology
- Jonathan P. Renn
- Vaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Niraj H. Tolia
- Host-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Patrick E. Duffy
- Pathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- DOI
- https://doi.org/10.1038/s41467-021-21955-1
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Vaccines that interrupt malaria transmission will be important tools for malaria elimination. Here the authors identify a human monoclonal antibody from Pfs230 vaccinated individuals that blocks transmission of Plasmodium falciparum to mosquitoes in a complement-dependent manner and reacts with gamete surface.
